Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul J M, Barry R, Inchauspé G
Transgene S.A., Site AFSSA, 31 avenue Tony Garnier, 69364 Lyon Cédex 07, France.
Vaccine. 2007 Oct 16;25(42):7339-53. doi: 10.1016/j.vaccine.2007.08.020. Epub 2007 Aug 31.
We designed and evaluated in HLA-class I transgenic mouse models a hepatitis C virus (HCV) T cell-based MVA vectored vaccine expressing three viral antigens known to be targets of potent CD8+- and CD4+-mediated responses. An accelerated (3 week-based) vaccination induced specific CD8+ T cells harboring two effector functions (cytolytic activity - both in vitro and in vivo- and production of IFNgamma) as well as specific CD4+ T cells recognizing all three vaccine antigens. Responses were long lasting (6 months), boostable by a fourth MVA vaccination and in vivo cross-reactive as demonstrated in a surrogate Listeria-based challenge assay. This candidate vaccine has now moved into clinical trials.
我们在HLA - I类转基因小鼠模型中设计并评估了一种基于丙型肝炎病毒（HCV）T细胞的MVA载体疫苗，该疫苗表达三种已知为强效CD8 +和CD4 +介导反应靶点的病毒抗原。加速（基于3周）接种疫苗诱导出具有两种效应功能（体外和体内的细胞溶解活性以及IFNγ的产生）的特异性CD8 + T细胞，以及识别所有三种疫苗抗原的特异性CD4 + T细胞。反应持续时间长（6个月），可通过第四次MVA接种加强，并且在基于李斯特菌的替代攻击试验中证明具有体内交叉反应性。这种候选疫苗现已进入临床试验阶段。
